Dapagliflozin
ATC Code
A10BK01
Dapagliflozin
Definition
A selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity. Dapagliflozin selectively and potently inhibits SGLT2 compared to SGLT1, which is the cotransporter of glucose in the gut.
Also known as BMS-512148-05, D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-, (1S)-, Compd. with (2S)-1,2-propanediol, Hydrate (1:1:1), DAPAGLIFLOZIN — per NCIT
Also identified as
- ATC A10BK01 per RXNORM
- NCIT NCIT:C78126 per NCIT
- SCTID 703674001 per RXNORM
- SCTID 703678003 per RXNORM
- UNII 1ULL0QJ8UC per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Diabetes mellitus type 2 | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Alimentary part of gastrointestinal system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Pancreas | may treat a disease of this organ | DERIVED · CC BY 4.0 |
2 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.